Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass …

MC Morice, PW Serruys, AP Kappetein, TE Feldman… - Circulation, 2010 - Am Heart Assoc
Background—The prospective, multinational, randomized Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to …

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass …

MC Morice, PW Serruys, AP Kappetein, TE Feldman… - Circulation, 2010 - europepmc.org
Background The prospective, multinational, randomized Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to …

[引用][C] Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxell-Eluting Stents or Coronary …

MC MORICE, PW SERRUYS… - … (New York, NY), 2010 - pascal-francis.inist.fr
Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous
Coronary Intervention Using Paclitaxell-Eluting Stents or Coronary Artery Bypass Graft …

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass …

MC Morice, PW Serruys, AP Kappetein… - …, 2010 - mayoclinic.elsevierpure.com
BACKGROUND-: The prospective, multinational, randomized Synergy Between
Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was …

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass …

MC Morice, PW Serruys, AP Kappetein, TE Feldman… - 2010 - pubmed.ncbi.nlm.nih.gov
Background The prospective, multinational, randomized Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to …

Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery …

MC Morice, PW Serruys, AP Kappetein, TE Feldman… - Circulation, 2010 - diva-portal.org
Background: The prospective, multinational, randomized Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to …

Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery …

MC Morice, PW Serruys, AP Kappetein, TE Feldman… - Circulation, 2010 - swepub.kb.se
Background: The prospective, multinational, randomized Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to …

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass …

MC Morice, P Serruys, AP Kappetein, T Feldman… - Circulation …, 2010 - repub.eur.nl
BACKGROUND-: The prospective, multinational, randomized Synergy Between
Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was …

Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery …

MC Morice, PW Serruys, AP Kappetein, TE Feldman… - Circulation, 2010 - cir.nii.ac.jp
< jats: p>< jats: bold>< jats: italic> Background—</jats: italic></jats: bold> The prospective,
multinational, randomized Synergy Between Percutaneous Coronary Intervention With …

Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery …

MC Morice, PW Serruys, AP Kappetein, TE Feldman… - Circulation, 2010 - swepub.kb.se
Background: The prospective, multinational, randomized Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to …